Patents by Inventor Orest Olejnik

Orest Olejnik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120065141
    Abstract: Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer.
    Type: Application
    Filed: July 14, 2011
    Publication date: March 15, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Patrick M. HUGHES, Orest OLEJNIK
  • Patent number: 8007828
    Abstract: Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: August 30, 2011
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Orest Olejnik
  • Publication number: 20110076318
    Abstract: Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.
    Type: Application
    Filed: December 7, 2010
    Publication date: March 31, 2011
    Inventors: Patrick M. Hughes, Orest Olejnik, Glenn Tony Huang, Joan-En Chang-Lin, Thierry Nivaggioli, JaneGuo Shiah, Michele Boix, Christian Sarrazin
  • Publication number: 20100331430
    Abstract: The invention provides ophthalmic compositions preserved using propionic preservative components alone or in combination with at least one additional preservative. In particular, an improvement in anti-microbial activity against bacteria is seen in addition to activity specific to fungal organisms and/or mold.
    Type: Application
    Filed: June 28, 2010
    Publication date: December 30, 2010
    Applicant: ALLERGAN, INC.
    Inventor: Orest Olejnik
  • Publication number: 20100222587
    Abstract: Membrane transporter-targeted therapeutic agents and methods of making and using the same.
    Type: Application
    Filed: March 23, 2010
    Publication date: September 2, 2010
    Applicant: ALLERGAN,INC.
    Inventors: Patrick M. HUGHES, Orest Olejnik, Joan-En Chang-Lin
  • Patent number: 7714024
    Abstract: Membrane transporter-targeted therapeutic agents and methods of making and using the same.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: May 11, 2010
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Orest Olejnik, Joan-En Chang-Lin
  • Patent number: 7691381
    Abstract: Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: April 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Orest Olejnik
  • Publication number: 20100068244
    Abstract: Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer.
    Type: Application
    Filed: October 9, 2009
    Publication date: March 18, 2010
    Applicant: ALLERGAN, INC.
    Inventors: Patrick M. Hughes, Orest Olejnik
  • Publication number: 20090312337
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: June 11, 2009
    Publication date: December 17, 2009
    Applicant: ALLERGAN, INC.
    Inventors: Richard S. Graham, Peter G. Bakhit, Orest Olejnik
  • Publication number: 20090163550
    Abstract: Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.
    Type: Application
    Filed: February 18, 2009
    Publication date: June 25, 2009
    Applicant: ALLERGAN, INC.
    Inventors: Patrick M. HUGHES, Orest Olejnik, Glenn Tony Huang, Joan-En Chang-Lin, Thierry Nivaggioli, JaneGuo Shiah, Michele Boix, Christian Sarrazin
  • Patent number: 7479134
    Abstract: A needleless microprotrusion method for infusion of a medicament into a patient includes disposing a substrate plurality of microprotrusions onto a patients' palm. A chemodenervating agent is disposed for delivery by the microprotrusions and the substrate supports and conforms the microprotrusions to the patients' palm in order to enable uniform penetration of the microprotrusions into the corneum.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: January 20, 2009
    Assignee: Allergan, Inc.
    Inventors: Orest Olejnik, Robert T. Lyons, Scott J. Gerondale
  • Publication number: 20080221524
    Abstract: A needleless microprotrusion system for infusion of a medicament into a patient includes a plurality of microprotrusions having a length sufficient to penetrate a stratum corneum of the patient. A chemodenervating agent is disposed for delivery by the microprotrusions and a substrate is provided for supporting the microprotrusions and conforming the microprotrusions to a patient's fossa axilaaris in order to enable uniform penetration of the microprotrusions into the corneum.
    Type: Application
    Filed: May 20, 2008
    Publication date: September 11, 2008
    Inventors: OREST OLEJNIK, Robert T. Lyons, Scott J. Gerondale
  • Publication number: 20080213338
    Abstract: An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof.
    Type: Application
    Filed: April 25, 2008
    Publication date: September 4, 2008
    Inventors: Orest Olejnik, Patrick M. Hughes, John S. Kent
  • Publication number: 20080207494
    Abstract: Cyclosporin A compositions are disclosed herein comprising an oil and a surfactant. These are useful in the treatment of dry eye disease.
    Type: Application
    Filed: July 12, 2006
    Publication date: August 28, 2008
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Patent number: 7390318
    Abstract: A needleless microprotrusion system for infusion of a medicament into a patient includes a plurality of microprotrusions having a length sufficient to penetrate a stratum corneum of the patient. A chemodenervating agent is disposed for delivery by the microprotrusions and a substrate is provided for supporting the microprotrusions and conforming the microprotrusions to a patient's palm in order to enable uniform penetration of the microprotrusions into the corneum.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: June 24, 2008
    Assignee: Allergan, Inc.
    Inventors: Orest Olejnik, Robert T. Lyons, Scott J. Gerondale
  • Publication number: 20080145407
    Abstract: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.
    Type: Application
    Filed: October 31, 2007
    Publication date: June 19, 2008
    Applicant: ALLERGAN, INC.
    Inventors: Glenn T. Huang, Thierry Nivaggioli, Lon T. Spada, Hiroshi Sugimoto, Wendy M. Blanda, James N. Chang, Orest Olejnik
  • Patent number: 7384648
    Abstract: An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: June 10, 2008
    Assignee: Allergan, Inc.
    Inventors: Orest Olejnik, Patrick M. Hughes, John S. Kent
  • Publication number: 20080107719
    Abstract: A transdermal drug delivery system includes a drug source, an adhesive for applying the system to a skin surface, a penetration enhancer for enhancing penetration of the drug into the skin surface, an energy source and a contact for conveying energy from said energy source through said adhesive and the penetrating enhancer.
    Type: Application
    Filed: November 8, 2006
    Publication date: May 8, 2008
    Inventors: Sukhon Likitlersuang, Chin-Ming Chang, James Chang, Orest Olejnik
  • Publication number: 20080070834
    Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.
    Type: Application
    Filed: November 15, 2007
    Publication date: March 20, 2008
    Inventors: James Chang, Orest Olejnik, Bruce Firestone
  • Patent number: 7332526
    Abstract: Compositions, methods, and pharmaceutical products related to prostaglandin-related compounds and trefoil factor family peptides are disclosed herein. Of particular interest are compositions and methods useful for the treatment of glaucoma with a reduced occurrence of hyperemia.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: February 19, 2008
    Assignee: Allergan, Inc.
    Inventors: Peter G. Bakhit, Richard Graham, Orest Olejnik